Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review

Gouveia, Andre G; Chan, Dominic C.W.; Hoskin, Peter; Marta, Gustavo Nader; Trippa, Fabio; Maranzano, Ernesto; Chow, Edward; Silva, Maurício F.

doi:10.1016/j.radonc.2021.07.022

Cited by 12 publications

(9 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data on the pain control with the use of SBRT compared with conventional palliative RT are conflicting. Some studies showed a higher pain relief with SBRT than with conventional RT (33)(34)(35)(36), others did not demonstrate any difference (36,37).…”

Section: Rt For Bone Metastasesmentioning

confidence: 99%

Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review

Kępka¹

2023

Transl Cancer Res

View full text Add to dashboard Cite

Background and Objective: Role of radiotherapy (RT) in the era of immuno-oncology (IO) in advanced non-small cell lung cancer (NSCLC) is rapidly changing. RT is not only intended for addressing palliation symptoms but also is considered as a potential tool potentializing an immunogenic effect of given drugs.However, the best timing, techniques, doses, volumes, and its use for asymptomatic patients is a subject of research. We performed a review on the role of palliative RT schedules in combination with IO for advanced NSCLC. Indications in symptomatic and asymptomatic patients, outcomes, toxicity, and possible developments are discussed.Methods: A literature search was conducted in MEDLINE and PubMed databases and clinicaltrials.gov using the keywords 'lung cancer' AND "immunotherapy" AND 'radiotherapy' OR "palliative radiotherapy".

show abstract

Section: Rt For Bone Metastasesmentioning

confidence: 99%

Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review

Kępka¹

2023

Transl Cancer Res

View full text Add to dashboard Cite

show abstract

“…[ 9 ] Especially for one‐shot irradiation at moderate doses, it is as effective in tumor cell killing as multifractionated treatment and has an even higher retreatment rate than multifractionated treatment with a relatively less toxic effect on the surrounding late‐responding normal tissues. [ 10–12 ] At the same time, surviving cancer cells after single‐dose irradiation had a stronger immunogenic phenotype and were more sensitive to immune inhibitors than those after multiple fractionated RT. [ 13 ] In addition, RT can not only directly kill cancer cells by selectively acting on cancer areas, but also promote the polarization of TAMs into pro‐inflammatory M1‐like phenotype with anticancer properties to kill cancer cells.…”

Section: Introductionmentioning

confidence: 99%

“…[9] Especially for one-shot irradiation at moderate doses, it is as effective in tumor cell killing as multifractionated treatment and has an even higher retreatment rate than multifractionated treatment with a relatively less toxic effect on the surrounding late-responding normal tissues. [10][11][12] At the same time, surviving cancer cells after single-dose irradiation had a stronger Immunotherapy shows immense promise for improving cancer treatment. Combining immunotherapy with radiotherapy provides a conspicuous advantage due to its enhanced abscopal effect.…”

mentioning

confidence: 99%

DNA Nanoclusters Combined with One‐Shot Radiotherapy Augment Cancer Immunotherapy Efficiency

Xie

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

A key clinical strategy to improve cancer immunotherapy is to combine with radiotherapy (RT) to boost the abscopal effect, a phenomenon in RT where local tumor treatment induces systemic regression of metastatic lesions. [2][3][4] However, radiationinduced macrophage accumulation and infiltration in the irradiated tumor is one of the key factors for cancer recurrence and metastasis. Recognizing and killing the residual surviving cancer cells after RT by persistently and stably stimulating immune response is an effective strategy to prevent cancer recurrence and distant metastasis.Tumor with a high density of tumorassociated macrophages (TAMs) is characterized by a high mortality rate and poor prognosis with a high tendency of recurrence and metastasis. [5][6][7][8] RT is currently well considered as one of the most effective remedies for cancer. [9] Especially for one-shot irradiation at moderate doses, it is as effective in tumor cell killing as multifractionated treatment and has an even higher retreatment rate than multifractionated treatment with a relatively less toxic effect on the surrounding late-responding normal tissues. [10][11][12] At the same time, surviving cancer cells after single-dose irradiation had a stronger Immunotherapy shows immense promise for improving cancer treatment. Combining immunotherapy with radiotherapy provides a conspicuous advantage due to its enhanced abscopal effect. However, established immune tolerance mechanisms in the tumor microenvironment can hamper the generation of a sufficient abscopal effect. Herein, a type of DNA nanocluster (DNAnc) that is self-assembled by a CpG-ODNs-loaded Y-shaped doublestranded DNA vector based on the unique complementary base-pairing rules is designed. The unique structure of DNAnc makes it load more than ≈8125.5 ± 822.5 copies of CpG ODNs within one single nanostructure, which effectively increases resistance to nuclease degradation and elevates the efficiency of repolarizing macrophages to an M1-like phenotype. Mechanistic studies reveal that more DNAncs are endocytosed by macrophages in the cancer tissue and repolarized macrophages to elicit a robust abscopal effect with the accumulation of macrophages induced by radiotherapy, generating potent, long-term, and durable antitumor immunity for the inhibition of tumor metastasis and the prevention of tumor recurrence, which provides a novel strategy to boost cancer immunotherapy.

show abstract

“…Studies have reported that distant metastatic lesions in patients with advanced BC are mostly found in the bones, simultaneously the most common primary site of bone metastasis is also breast [11] , [12] , [13] . Once bone metastasis occurs, patients often present with bone or joint pain, pathological fractures, or neuropathic pain [14] , [15] . Patients with metastatic breast cancer in bones (MBCB) are usually not able to be cured by available treatment options, and they often die from multiorgan failure within five years [13] .…”

Section: Introductionmentioning

confidence: 99%

How has the field of metastatic breast cancer in bones evolved over the past 22 years?

Chen¹,

Guo²,

He³

et al. 2023

Journal of Bone Oncology

View full text Add to dashboard Cite

Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review

Cited by 12 publications

References 158 publications

Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review

Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review

DNA Nanoclusters Combined with One‐Shot Radiotherapy Augment Cancer Immunotherapy Efficiency

How has the field of metastatic breast cancer in bones evolved over the past 22 years?

Contact Info

Product

Resources

About